MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
- PMID: 12609962
- DOI: 10.1182/blood.V101.6.2368
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
Abstract
Inappropriate expression of the multidrug resistance (MDR1) gene encoding the P-glycoprotein (Pgp) has been frequently implicated in resistance to different chemotherapeutic drugs. We have previously generated chronic myeloid leukemia (CML) cell lines resistant to the tyrosine kinase inhibitor imatinib mesylate (STI571), and one line (LAMA84-r) showed overexpression not only of the Bcr-Abl protein but also of Pgp. In the present study, we investigated this phenomenon in other cell lines overexpressing exclusively Pgp. Thus, cells from the K562/DOX line, described as resistant to doxorubicin due to MDR1 gene overexpression, grew continuously in the presence of 1 microM imatinib, but died in 4 to 5 days if the Pgp pump modulators verapamil or PSC833 were added to the imatinib-treated culture. Analysis of cell proliferation by the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay confirmed the differential sensitivity of K562/DOX to imatinib, which was also reversed by verapamil or PSC833. Flow cytometric analysis of the total phosphotyrosine content by intracytoplasmic staining after a 2-hour incubation with escalating doses of imatinib showed that the inhibitory concentrations of 50% (IC(50)) for inhibition of cellular protein tyrosine phosphorylation were 15, 10, and 5 microM for K562/DOX, K562/DOX plus verapamil, and K562, respectively. Retroviral-mediated transfection of the BCR-ABL(+) AR230 cell line with the MDR1 gene decreased its sensitivity to imatinib, an effect that was also reversed by verapamil. The possible role of MDR overexpression in clinical resistance to imatinib remains to be defined. We therefore confirm that imatinib should be added to the extensive list of drugs that can be affected by the MDR phenomenon.
Comment in
-
Functional consequence of MDR1 expression on imatinib intracellular concentrations.Blood. 2003 Aug 1;102(3):1142. doi: 10.1182/blood-2003-03-0993. Blood. 2003. PMID: 12869489 No abstract available.
Similar articles
-
Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.Leuk Lymphoma. 2011 Nov;52(11):2139-47. doi: 10.3109/10428194.2011.591013. Epub 2011 Jun 30. Leuk Lymphoma. 2011. PMID: 21718141
-
Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.Asian Pac J Cancer Prev. 2014;15(11):4555-61. doi: 10.7314/apjcp.2014.15.11.4555. Asian Pac J Cancer Prev. 2014. PMID: 24969884
-
In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.Exp Hematol. 2002 Jul;30(7):729-37. doi: 10.1016/s0301-472x(02)00836-6. Exp Hematol. 2002. PMID: 12135670
-
Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias.Curr Opin Oncol. 2002 Nov;14(6):616-20. doi: 10.1097/00001622-200211000-00005. Curr Opin Oncol. 2002. PMID: 12409651 Review.
-
[Preclinical and clinical profile of imatinib mesilate, a potent protein-tyrosine kinase inhibitor for CML therapy].Nihon Yakurigaku Zasshi. 2003 Feb;121(2):119-28. doi: 10.1254/fpj.121.119. Nihon Yakurigaku Zasshi. 2003. PMID: 12616857 Review. Japanese.
Cited by
-
The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.Leuk Res Treatment. 2012;2012:671702. doi: 10.1155/2012/671702. Epub 2012 Apr 24. Leuk Res Treatment. 2012. PMID: 23259070 Free PMC article.
-
Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib.Sci Rep. 2016 Jul 12;6:29559. doi: 10.1038/srep29559. Sci Rep. 2016. PMID: 27405085 Free PMC article.
-
Philadelphia chromosome-positive acute lymphoblastic leukemia.Hematol Oncol Clin North Am. 2009 Oct;23(5):1043-63, vi. doi: 10.1016/j.hoc.2009.07.007. Hematol Oncol Clin North Am. 2009. PMID: 19825452 Free PMC article. Review.
-
Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.Pharm Res. 2008 Apr;25(4):827-35. doi: 10.1007/s11095-007-9376-3. Epub 2007 Oct 13. Pharm Res. 2008. PMID: 17934801
-
Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor.Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12843-8. doi: 10.1073/pnas.0511076103. Epub 2006 Aug 14. Proc Natl Acad Sci U S A. 2006. PMID: 16908864 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous